Detail (Long)
Phase 3 ACTT-3 Trial Reveals No Greater Benefit With Interferon Beta-1a Plus Remdesivir Versus Remdesivir Alone In Hospitalized Patients With COVID-19 Pneumonia; <a href=https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00384-2/fulltext><b><u>access <i>Lancet Respir Med</i> article</u></b></a>